ArticlePakistan journal of medical sciences2026
Unraveling clinical and biological predictors of successful treatment free remission in Chronic Myeloid Leukemia and its impact on the healthcare system in a low- and middle-income country.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tyrosine Kinase Inhibitors (TKIs) have revolutionized the management of Chronic Myeloid Leukemia (CML), making treatment free remission (TFR) possible in eligible patients. However, TFR data in Pakistan remains scarce. This study aimed to evaluate relapse-free survival (RFS) outcomes and identify clinical predictors of successful TFR in CML patients. Methodology: Adult CML (chronic phase) patients > 18 years, eligible for TFR were included. It was an observational (cohort based study) and was conducted between 2022 and 2025 at Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi. Minimum required duration of TKI was > 3 years and duration of DMR was > 2 years. Data was collected from bone marrow transplant center. Results: Thirty patients (16 males and 14 females) attempting TFR were analyzed. Median age at diagnosis was 34.5 years (range 19 - 60) and the median age at discontinuation was 38.5 years (range 24-63). Most patients had an intermediate SOKAL risk score (56.7%, n=17), while 30% (n=9) were low risk and 13.3% (n=4) had high risk. Imatinib was the most frequently used first-line TKI (83.3%, n=25), followed by nilotinib (16.7%, n=5). The median treatment duration of TKI was 40 months (range 36-60), and the median duration of sustained deep molecular response before attempting TFR was 30.5 months (range 24-49). RFS was 80% at six months and 66.7% at 12 months. Depth and duration of DMR and SOKAL scores positively defined the success of TFR with depth of DMR achieving significance levels. Relapsed patients (9 out of 10) had high or intermediate SOKAL risk scores. Conclusion: Despite limited data available for Pakistan, TFR remains a viable and safe option in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.